TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib.

about

TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib.

Item

http://www.wikidata.org/entity/Q55538878

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

TP53 mutations predict for poo ...... ients treated with crizotinib.

@en

TP53 mutations predict for poo ...... ients treated with crizotinib.

@nl

type

Item

label

TP53 mutations predict for poo ...... ients treated with crizotinib.

@en

TP53 mutations predict for poo ...... ients treated with crizotinib.

@nl

prefLabel

TP53 mutations predict for poo ...... ients treated with crizotinib.

@en

TP53 mutations predict for poo ...... ients treated with crizotinib.

@nl

P1476

TP53 mutations predict for poo ...... tients treated with crizotinib

@en

P2093

Chun-Wei Xu

http://www.w3.org/2001/XMLSchema#string

Fang-Fang Chen

http://www.w3.org/2001/XMLSchema#string

Gang Chen

http://www.w3.org/2001/XMLSchema#string

Jian-Ping Lu

http://www.w3.org/2001/XMLSchema#string

Li-Hua Zhong

http://www.w3.org/2001/XMLSchema#string

Rong-Rong Chen

http://www.w3.org/2001/XMLSchema#string

Tang-Feng Lv

http://www.w3.org/2001/XMLSchema#string

Wei Liu

http://www.w3.org/2001/XMLSchema#string

Wei-Feng Zhu

http://www.w3.org/2001/XMLSchema#string

Wen-Xian Wang

http://www.w3.org/2001/XMLSchema#string

P2860

ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.

Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer.

TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data.

P304

2991-2998

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/JTD.2018.04.98

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29997966

http://www.w3.org/2001/XMLSchema#string

P921

crizotinib

P932

6006073

http://www.w3.org/2001/XMLSchema#string